Inj crizanlizumab-tmca 5mg
Products billed under this code include Adakveo.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Adakveo.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Adakveo | Novartis Pharmaceuticals Corporation | 00078-0883-61 | 20 | $2,598.98 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $129.949 | +$0.012 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted September 17, 2026 |
| 3Q26 | $129.937 | −$0.007 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted September 15, 2026 |
| 2Q26 | $129.944 | +$0.351 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted September 15, 2026 |
| 1Q26 | $129.593 | +$0.113 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted September 15, 2026 |
| 4Q25 | $129.48 | −$0.098 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted September 8, 2026 |
| 3Q25 | $129.578 | +$0.076 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted March 10, 2026 |
| 2Q25 | $129.502 | +$0.822 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted March 10, 2026 |
| 1Q25 | $128.68 | +$0.142 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted December 19, 2025 |
| 4Q24 | $128.538 | +$1.151 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 11, 2025 |
| 3Q24 | $127.387 | +$0.036 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 11, 2025 |
| 2Q24 | $127.351 | +$0.249 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted March 11, 2025 |
| 1Q24 | $127.102 | +$0.245 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted December 19, 2024 |
| 4Q23 | $126.857 | +$0.251 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted October 10, 2024 |
| 3Q23 | $126.606 | +$1.325 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 5, 2024 |
| 2Q23 | $125.281 | +$0.153 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted February 23, 2024 |
| 1Q23 | $125.128 | +$0.505 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted December 6, 2023 |
| 4Q22 | $124.623 | −$0.434 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 22, 2023 |
| 3Q22 | $125.057 | +$0.876 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 9, 2023 |
| 2Q22 | $124.181 | +$0.059 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted December 14, 2022 |
| 1Q22 | $124.122 | +$0.831 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 8, 2022 |
| 4Q21 | $123.291 | +$0.012 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 2, 2022 |
| 3Q21 | $123.279 | +$0.845 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted June 2, 2022 |
| 2Q21 | $122.434 | +$0.009 | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted March 1, 2022 |
| 1Q21 | $122.425 | – | 5 MG | Inj crizanlizumab-tmca 5mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.